EGFR 3′UTR 774T>C polymorphism contributes to bladder cancer risk

Mutagenesis

Volumn 28, Issue 1, 2013, Pages 49-55

  Chu, Haiyan ^a   Wang, Meilin ^a   Jin, Hua ^b   Lv, Qiang ^c   Wu, Dongmei ^a   Tong, Na ^a   Ma, Lan ^a   Shi, Danni ^a   Zhong, Dongyan ^a   Fu, Guangbo ^a   Yuan, Lin ^d   Qin, Chao ^c   Yin, Changjun ^c   Zhang, Zhengdong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nantong Cancer Hospital   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA 214; EGFR PROTEIN, HUMAN; MICRORNA; MIRN124 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CANCER STAGING; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK ASSESSMENT; RNA BINDING; SUBSTITUTION REACTION; ASIAN; BLADDER TUMOR; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

3' UNTRANSLATED REGIONS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; URINARY BLADDER NEOPLASMS;

EID: 84871746880     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/ges051     Document Type: Article

References (67)

1. Kakehi, Y., Hirao, Y., Kim, W. J., Ozono, S., Masumori, N., Miyanaga, N., Nasu, Y. and Yokomizo, A. (2010) Bladder Cancer Working Group report. Jpn. J. Clin. Oncol., 40 Suppl 1, i57-i64
2. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. and Thun, M. J. (2007) Cancer statistics, 2007. CA Cancer J. Clin., 57, 43-66
3. Burch, J. D., Rohan, T. E., Howe, G. R., Risch, H. A., Hill, G. B., Steele, R. and Miller, A. B. (1989) Risk of bladder cancer by source and type of tobacco exposure: A case-control study. Int. J. Cancer, 44, 622-628 (Pubitemid 19258734)
4. Wilhelm-Benartzi, C. S., Christensen, B. C., Koestler, D. C., Andres Houseman, E., Schned, A. R., Karagas, M. R., Kelsey, K. T. and Marsit, C. J. (2011) Association of secondhand smoke exposures with DNA methylation in bladder carcinomas. Cancer Causes Control, 22, 1205-1213
5. Alberg, A. J., Kouzis, A., Genkinger, J. M., Gallicchio, L., Burke, A. E., Hoffman, S. C., Diener-West, M., Helzlsouer, K. J. and Comstock, G. W. (2007) A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke. Am. J. Epidemiol., 165, 660-666 (Pubitemid 46348371)
6. Vineis, P. and Simonato, L. (1991) Proportion of lung and bladder cancers in males resulting from occupation: A systematic approach. Arch Environ Health, 46, 6-15
7. Kirkali, Z., Chan, T., Manoharan, M., et al. (2005) Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology, 66, 4-34 (Pubitemid 43049607)
8. Popp, W., Schmieding, W., Speck, M., Vahrenholz, C. and Norpoth, K. (1992) Incidence of bladder cancer in a cohort of workers exposed to 4-chloro-o-toluidine while synthesising chlordimeform. Br. J. Ind. Med., 49, 529-531
9. Steenland, K. and Palu, S. (1999) Cohort mortality study of 57,000 painters and other union members: A 15 year update. Occup. Environ. Med., 56, 315-321 (Pubitemid 29195183)
10. Kogevinas, M., 't Mannetje, A., Cordier, S., et al. (2003) Occupation and bladder cancer among men in Western Europe. Cancer Causes Control, 14, 907-914 (Pubitemid 38091211)
11. Wells, A. (1999) EGF receptor. Int J Biochem Cell Biol, 31, 637-643 (Pubitemid 29248872)
12. Jorissen, R. N., Walker, F., Pouliot, N., Garrett, T. P., Ward, C. W. and Burgess, A. W. (2003) Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res, 284, 31-53 (Pubitemid 36331965)
13. Lin, S. Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L. and Hung, M. C. (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol., 3, 802-808 (Pubitemid 32842685)
14. Neal, D. E., Sharples, L., Smith, K., Fennelly, J., Hall, R. R. and Harris, A. L. (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 65, 1619-1625 (Pubitemid 20106125)
15. Vet, J. A., Debruyne, F. M. and Schalken, J. A. (1994) Molecular prognostic factors in bladder cancer. World J. Urol., 12, 84-88
16. Arteaga, C. L. (2001) The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol., 19, 32S-40S (Pubitemid 32880077)
17. Brandt, B., Hermann, S., Straif, K., Tidow, N., Buerger, H. and Chang-Claude, J. (2004) Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res., 64, 7-12 (Pubitemid 38114073)
18. Gebhardt, F., Zanker, K. S. and Brandt, B. (1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem., 274, 13176-13180
19. Liu, W., Innocenti, F., Wu, M. H., Desai, A. A., Dolan, M. E., Cook, E. H. Jr and Ratain, M. J. (2005) A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res., 65, 46-53 (Pubitemid 40070794)
20. Liu, W., He, L., Ramirez, J., Krishnaswamy, S., Kanteti, R., Wang, Y. C., Salgia, R. and Ratain, M. J. (2011) Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res., 71, 2423-2427
21. Mason, R. A., Morlock, E. V., Karagas, M. R., Kelsey, K. T., Marsit, C. J., Schned, A. R. and Andrew, A. S. (2009) EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis, 30, 1155-1160
22. Lee, J. M., Yang, S. Y., Yang, P. W., et al. (2011) Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. Ann. Surg. Oncol., 18, 2066-2073
23. Choi, J. E., Park, S. H., Kim, K. M., et al. (2007) Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: A case-control study. BMC Cancer, 7, 199
24. Bartel, D. P. (2004) MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116, 281-297
25. Carthew, R. W. (2006) Gene regulation by microRNAs. Curr. Opin. Genet. Dev., 16, 203-208 (Pubitemid 43376069)
26. Pillai, R S. (2005) MicroRNA function: Multiple mechanisms for a tiny RNA? RNA, 11, 1753-1761 (Pubitemid 41720024)
27. Garzon, R., Fabbri, M., Cimmino, A., Calin, G. A. and Croce, C. M. (2006) MicroRNA expression and function in cancer. Trends Mol. Med., 12, 580-587 (Pubitemid 44780201)
28. Saunders, M. A., Liang, H. and Li, W. H. (2007) Human polymorphism at microRNAs and microRNA target sites. Proc. Natl Acad. Sci. USA, 104, 3300-3305 (Pubitemid 46364154)
29. Clop, A., Marcq, F., Takeda, H., et al. (2006) A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat. Genet., 38, 813-818 (Pubitemid 43980603)
30. Georges, M., Coppieters, W. and Charlier, C. (2007) Polymorphic miRNA-mediated gene regulation: Contribution to phenotypic variation and disease. Curr. Opin. Genet. Dev., 17, 166-176 (Pubitemid 46843549)
31. Sethupathy, P. and Collins, F. S. (2008) MicroRNA target site polymorphisms and human disease. Trends Genet., 24, 489-497
32. Chen, K., Song, F., Calin, G. A., Wei, Q., Hao, X. and Zhang, W. (2008) Polymorphisms in microRNA targets: A gold mine for molecular epidemiology. Carcinogenesis, 29, 1306-1311
33. Blitzblau, R. C. and Weidhaas, J. B. (2010) MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk. Mol. Diagn. Ther., 14, 335-342
34. Zhang, S., Chen, H., Zhao, X., Cao, J., Tong, J., Lu, J., Wu, W., Shen, H., Wei, Q. and Lu, D. (2012) REV3L 3′UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility. Oncogene, 2012 Feb 20 [Epub ahead of print], doi:10.1038/onc.2012.32
35. Wang, M., Wang, M., Yuan, L., Wu, D., Zhang, Z., Yin, C., Fu, G., Wei, Q. and Zhang, Z. (2010) A novel XPF -357A>C polymorphism predicts risk and recurrence of bladder cancer. Oncogene, 29, 1920-1928
36. Mazumder, B., Seshadri, V. and Fox, P. L. (2003) Translational control by the 3′-UTR: The ends specify the means. Trends Biochem. Sci., 28, 91-98 (Pubitemid 36165138)
37. Wang, K., Yamamoto, H., Chin, J. R., Werb, Z. and Vu, T. H. (2004) Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J. Biol. Chem., 279, 53848-53856 (Pubitemid 40051894)
38. Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D. and Tarnawski, A. S. (2002) Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med., 8, 289-293 (Pubitemid 34250108)
39. Nomura, M., Shigematsu, H., Li, L., et al. (2007) Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med., 4, e125
40. Wang, W. S., Chen, P. M., Chiou, T. J., Liu, J. H., Lin, J. K., Lin, T. C., Wang, H. S. and Su, Y. (2007) Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin. Cancer Res., 13, 3597-3604 (Pubitemid 46955121)
41. Press, O. A., Zhang, W., Gordon, M. A., Yang, D., Lurje, G., Iqbal, S., El-Khoueiry, A. and Lenz, H. J. (2008) Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res., 68, 3037-3042 (Pubitemid 351556305)
42. Lurje, G., Nagashima, F., Zhang, W., et al. (2008) Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin. Cancer Res., 14, 7884-7895
43. Chin, L. J., Ratner, E., Leng, S., et al. (2008) A SNP in a let-7 micro- RNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res., 68, 8535-8540
44. Landi, D., Gemignani, F., Naccarati, A., et al. (2008) Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis, 29, 579-584 (Pubitemid 351404875)
45. Gao, Y., He, Y., Ding, J., et al. (2009) An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3′ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis, 30, 2064-2069
46. Wynendaele, J., Bohnke, A., Leucci, E., et al. (2010) An illegitimate micro- RNA target site within the 3′UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res., 70, 9641-9649
47. Liu, Z., Wei, S., Ma, H., Zhao, M., Myers, J. N., Weber, R. S., Sturgis, E. M. and Wei, Q. (2011) A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 32, 1668-1674
48. Jazdzewski, K., Boguslawska, J., Jendrzejewski, J., Liyanarachchi, S., Pachucki, J., Wardyn, K. A., Nauman, A. and de la Chapelle, A. (2011) Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J. Clin. Endocrinol. Metab., 96, E546-E553
49. Teo, M. T., Landi, D., Taylor, C. F., et al. (2012) The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis, 33, 581-586
50. Wei, H., Ke, H.L., Lin, J., Shete, S., Wood, C.G. and Hildebrandt, M.A. (2012) MicroRNA target site polymorphisms in the VHL-HIF1alpha pathway predict renal cell carcinoma risk. Mol. Carcinog., 2012 Apr 19 [Epub ahead of print], doi:10.1002/mc.21917
51. Wang, G., van der Walt, J. M., Mayhew, G., Li, Y. J., Zuchner, S., Scott, W. K., Martin, E. R. and Vance, J. M. (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am. J. Hum.Genet., 82, 283-289
52. Sethupathy, P., Borel, C., Gagnebin, M., Grant, G. R., Deutsch, S., Elton, T. S., Hatzigeorgiou, A. G. and Antonarakis, S. E. (2007) Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: A mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am. J. Hum. Genet., 81, 405-413 (Pubitemid 47236088)
53. Bar-Eli, M. (2011) Searching for the 'melano-miRs': MiR-214 drives melanoma metastasis. EMBO J, 30, 1880-1881
54. Yang, Z., Chen, S., Luan, X., Li, Y., Liu, M., Li, X., Liu, T. and Tang, H. (2009) MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life, 61, 1075-1082
55. Yang, H., Kong, W., He, L., et al. (2008) MicroRNA expression profiling in human ovarian cancer: MiR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res., 68, 425-433 (Pubitemid 351380068)
56. Chou, Y. T., Lin, H. H., Lien, Y. C., et al. (2010) EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res., 70, 8822-8831
57. Webster, R. J., Giles, K. M., Price, K. J., Zhang, P. M., Mattick, J. S. and Leedman, P. J. (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by icroRNA-7. J. Biol. Chem., 284, 5731-5741
58. Rai, K., Takigawa, N., Ito, S., Kashihara, H., Ichihara, E., Yasuda, T., Shimizu, K., Tanimoto, M. and Kiura, K. (2011) Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther., 10, 1720-1727
59. Xu, B., Wang, N., Wang, X., Tong, N., Shao, N., Tao, J., Li, P., Niu, X., Feng, N., Zhang, L., Hua, L., Wang, Z. and Chen, M. (2012) MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate, 72, 1171-1178
60. Katakowski, M., Zheng, X., Jiang, F., Rogers, T., Szalad, A. and Chopp, M. (2010) MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest., 28, 1024-1030
61. Li, Y., Vandenboom, T. G., II, Wang, Z., Kong, D., Ali, S., Philip, P. A. and Sarkar, F. H. (2010) miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res., 70, 1486-1495
62. Cho, W. C., Chow, A. S. and Au, J. S. (2011) MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol., 8, 125-131
63. Cho, W. C., Chow, A. S. and Au, J. S. (2009) Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur. J. Cancer, 45, 2197-2206
64. Zhou, X., Ren, Y., Moore, L., et al. (2010) Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab. vest., 90, 144-155
65. Seike, M., Goto, A., Okano, T., et al. (2009) MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl Acad. Sci. USA, 106, 12085-12090
66. Hayes, D. N. and McLeod, H. L. (2008) EGFR regulation by microRNA in lung cancer: A rose by any other name. is an increasingly complicated rose. Ann. Oncol., 19, 1036-1037
67. Tao, J., Wu, D., Xu, B., Qian, W., Li, P., Lu, Q., Yin, C. and Zhang, W. (2012) microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol. Rep., 27, 1967-1975.